Structure Therapeutics
GPCR
26.68
-0.79
-2.88%
Structure Therapeutics
US · GPCR
#2815 by market cap
Listed 2023
26.68
-0.79
-2.88%
Live - 5344 symbols - heartbeat 110s ago
· 2026-10-08 08:29
Pre-market
26.71
+0.11%
After-hours
27.00
+1.20%
Overnight
26.78
+0.37%
- Market cap
- 1.90B
- P/E (TTM)i
- -8.81
- P/Bi
- 1.40
- EPSi
- -2.40
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on GPCR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.8 percentage points.
Institutional ownership
- Held by institutions
- 102.53% -1.77pp
- Institutions
- 248 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund49.12%
Hedge Fund27.66%
VC/PE Fund18.20%
Public Company5.13%
Individual/Insider2.44%
Private Company1.02%
Government Pension Fund0.61%
Sovereign Wealth Fund0.60%
Insurance Company0.10%
Top holders as of 2026-06-30
FMR
10.90% · 7.78M sh
Deep Track Capital, LP
10.59% · 7.55M sh
Wellington Management Group
10.35% · 7.38M sh
Avoro Capital Advisors LLC
9.19% · 6.56M sh
Janus Henderson Group plc
7.30% · 5.20M sh
BVF Partners L.P.
4.72% · 3.37M sh
Morgan Stanley
3.84% · 2.74M sh
OrbiMed Advisors LLC
3.10% · 2.21M sh
Principal Global Investors, LLC
2.46% · 1.75M sh
American Century Investment Management
2.36% · 1.68M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 28 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| FMR | -- | 10.90% |
| Jun Yoon | Co- Founder, CFO & Secretary | 1.25% |
| Raymond Stevens | Chief Executive Officer | 1.06% |
| Daniel Welch | Independent Chairperson | 0.06% |
| Xichen Lin | Chief Scientific Officer | 0.03% |
| Blai Coll | Vice President of Clinical Development | 0.02% |
| Yingli Ma | Chief Technology Officer | 0.01% |
| Ashley Hall | Chief Development Officer | 0.01% |
| Sharon Tetlow | Independent Director | -- |
| Angus Russell | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-20 | Blai Coll | Vice President of Clinical Development | Other Disposition | -4,008 | -- |
| 2026-09-20 | Blai Coll | Vice President of Clinical Development | Other Derivative Acquisition | +4,008 | -- |
| 2026-09-20 | Blai Coll | Vice President of Clinical Development | Open Market Derivative Dispositi | -4,008 | -- |
| 2026-09-17 | Blai Coll | Vice President of Clinical Development | Sale to Issuer | -3,542 | $35.01 |
| 2026-08-31 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -17,817 | -- |
| 2026-08-31 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -5,939 | $45.86–47.83 |
| 2026-08-17 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -11,817 | -- |
| 2026-08-17 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -3,939 | $53.13–55.05 |
| 2026-08-05 | John Berrios | -- | Other Acquisition | +140,766 | -- |
| 2026-08-05 | John Berrios | -- | Other Derivative Acquisition | +174,612 | $17.54 |
| 2026-08-03 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -11,817 | -- |
| 2026-08-03 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -3,939 | $49.29–50.03 |
| 2026-07-13 | Xichen Lin | Chief Scientific Officer | Other Acquisition | +7,878 | -- |
| 2026-07-13 | Xichen Lin | Chief Scientific Officer | Open Market Disposition | -7,878 | $50.80–51.71 |
| 2026-07-13 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -23,634 | -- |
| 2026-07-13 | Xichen Lin | Chief Scientific Officer | Other Derivative Acquisition | +7,878 | -- |
| 2026-07-13 | Xichen Lin | Chief Scientific Officer | Open Market Derivative Dispositi | -7,878 | -- |
| 2026-06-24 | Xichen Lin | Chief Scientific Officer | Other Acquisition | +7,878 | -- |
| 2026-06-24 | Xichen Lin | Chief Scientific Officer | Open Market Disposition | -7,878 | $49.08 |
| 2026-06-24 | Xichen Lin | Chief Scientific Officer | Derivative Exercise and Sale | -23,634 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:29:49 · For reference only, not investment advice and not tailored to your situation.